Announcement • May 26
EMV Capital plc, Annual General Meeting, Jun 17, 2026 EMV Capital plc, Annual General Meeting, Jun 17, 2026. Location: panmure liberum limited, ropemaker place, level 12, 25 ropemaker street, ec2y 9ly, london United Kingdom Board Change • May 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Charles Alexander Spicer was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 20
EMV Capital plc Appoints Will Whitehorn OBE as Chairman of the Board of Directors EMV Capital plc announced, on January 2026, the company appointed Will Whitehorn OBE as Chairman of the Board of Directors. Will, formerly the first President of Virgin Galactic, played a vital role in launching commercial space travel and brings considerable expertise from the commercial space sector. Announcement • May 14
EMV Capital plc to Report Fiscal Year 2025 Final Results on May 19, 2026 EMV Capital plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on May 19, 2026 New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.8% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (UK£2.4m revenue, or US$3.2m). Market cap is less than US$100m (UK£13.1m market cap, or US$17.8m). Announcement • Feb 04
EMV Capital plc Provides Group Earnings Guidance for the Year Ending 31 December 2025 EMV Capital plc provided group earnings guidance for the year ending 31 December 2025. For the period, Group revenue expected to be approximately £2.8 million (FY24: £2.5 million), representing c.16% growth driven by higher corporate finance fees, increased fundraising activity and higher recurring fund management fees following the full operational integration of Martlet Capital. Announcement • Nov 24
EMV Capital plc Announces Chief Financial Officer Changes, Effective December 1, 2025 EMV Capital Plc announced the appointment of Anesh Patel as Group Chief Financial Officer (non-Board) with Stephen Crowe, the Company's current CFO, transitioning to a newly created role of Portfolio CFO (non-Board). Both changes are expected to take effect from 1 December 2025. The creation of these two distinct roles reflects EMVC's development into a business with over £100 million of Assets Under Management (AUM) and a portfolio of more than seventy companies, supported by multiple revenue streams across corporate finance, fund management, and value-creation services. As the Group has scaled, the scope of the finance function has naturally evolved, requiring a dedicated Group-focused CFO and a separate senior role focused exclusively on supporting portfolio company growth. Anesh Patel is an accomplished strategic finance leader with over twenty years of relevant experience. He qualified as a Chartered Accountant with Ernst & Young and his subsequent experience in investment banking and leadership roles within AIM-quoted life sciences companies closely align with EMVC's core areas of corporate finance, M&A projects, portfolio management and venture development. Stephen, who has been with the Company for over seven years, will support an orderly handover before concentrating full-time on providing senior financial and accounting services to selected EMVC portfolio companies (paid for by the portfolio companies), ensuring continuity and strengthening of the Group's active portfolio-management model. Board Change • Nov 18
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Executive Director, General Counsel & Group Company Secretary Ed Hooper is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 05
First half 2025 earnings released: UK£0.041 loss per share (vs UK£0.071 loss in 1H 2024) First half 2025 results: UK£0.041 loss per share (improved from UK£0.071 loss in 1H 2024). Revenue: UK£1.04m (down 8.0% from 1H 2024). Net loss: UK£1.13m (loss narrowed 33% from 1H 2024). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. New Risk • Sep 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£2.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.0m free cash flow). Earnings have declined by 7.0% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£2.5m revenue, or US$3.3m). Market cap is less than US$100m (UK£13.7m market cap, or US$18.5m). Announcement • Sep 18
EMV Capital plc to Report First Half, 2025 Results on Sep 30, 2025 EMV Capital plc announced that they will report first half, 2025 results on Sep 30, 2025 New Risk • Jun 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.0m free cash flow). Earnings have declined by 7.0% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (UK£2.5m revenue, or US$3.3m). Market cap is less than US$100m (UK£12.8m market cap, or US$17.2m). Announcement • Jun 09
EMV Capital plc, Annual General Meeting, Jun 30, 2025 EMV Capital plc, Annual General Meeting, Jun 30, 2025. Location: panmure liberum limited, ropemaker place, level 12, 25 ropemaker street, ec2y 9ly, london United Kingdom Reported Earnings • Jun 05
Full year 2024 earnings released: UK£0.13 loss per share (vs UK£0.11 loss in FY 2023) Full year 2024 results: UK£0.13 loss per share (further deteriorated from UK£0.11 loss in FY 2023). Revenue: UK£2.45m (up 70% from FY 2023). Net loss: UK£3.06m (loss widened 16% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Price Target Changed • Jun 04
Price target decreased by 11% to UK£1.33 Down from UK£1.49, the current price target is provided by 1 analyst. New target price is 224% above last closing price of UK£0.41. Stock is down 40% over the past year. The company posted a net loss per share of UK£0.11 last year. New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£12.1m market cap, or US$16.1m). New Risk • Jan 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.2m). Market cap is less than US$100m (UK£14.6m market cap, or US$18.1m). Announcement • Dec 05
EMV Capital plc has completed a Follow-on Equity Offering in the amount of £1.5 million. EMV Capital plc has completed a Follow-on Equity Offering in the amount of £1.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 914,496
Price\Range: £0.5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,765,504
Price\Range: £0.5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 100,000
Price\Range: £0.5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 220,000
Price\Range: £0.5 Announcement • Dec 03
EMV Capital plc has filed a Follow-on Equity Offering in the amount of £1.5 million. EMV Capital plc has filed a Follow-on Equity Offering in the amount of £1.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,240,000
Price\Range: £0.5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,660,000
Price\Range: £0.5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 100,000
Price\Range: £0.5 New Risk • Dec 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.3m). Market cap is less than US$100m (UK£12.7m market cap, or US$16.1m). Reported Earnings • Oct 03
First half 2024 earnings released: UK£0.071 loss per share (vs UK£0.058 loss in 1H 2023) First half 2024 results: UK£0.071 loss per share (further deteriorated from UK£0.058 loss in 1H 2023). Revenue: UK£1.13m (up 47% from 1H 2023). Net loss: UK£1.69m (loss widened 24% from 1H 2023). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. New Risk • Aug 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.2m free cash flow). Earnings have declined by 1.1% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Revenue is less than US$5m (UK£1.4m revenue, or US$1.8m). Market cap is less than US$100m (UK£14.5m market cap, or US$18.4m). New Risk • Jul 08
New major risk - Revenue and earnings growth Earnings have declined by 1.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.2m free cash flow). Earnings have declined by 1.1% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£1.4m revenue, or US$1.9m). Market cap is less than US$100m (UK£17.0m market cap, or US$21.8m). New Risk • Jun 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-UK£3.2m free cash flow). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Revenue is less than US$5m (UK£1.4m revenue, or US$1.8m). Market cap is less than US$100m (UK£17.9m market cap, or US$22.6m). Announcement • Jun 19
NetScientific plc, Annual General Meeting, Jul 10, 2024 NetScientific plc, Annual General Meeting, Jul 10, 2024. Location: panmure gordon uk limited, ropemaker place, level 12, 25 ropemaker street, ec2y 9ly, london United Kingdom Reported Earnings • Jun 15
Full year 2023 earnings released: UK£0.11 loss per share (vs UK£0.14 loss in FY 2022) Full year 2023 results: UK£0.11 loss per share (improved from UK£0.14 loss in FY 2022). Net loss: UK£2.64m (loss narrowed 15% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Announcement • May 31
NetScientific plc to Report Fiscal Year 2023 Results on Jun 13, 2024 NetScientific plc announced that they will report fiscal year 2023 results on Jun 13, 2024 New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.9% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Revenue is less than US$5m (UK£1.4m revenue, or US$1.7m). Market cap is less than US$100m (UK£13.9m market cap, or US$17.3m). New Risk • Feb 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.7m free cash flow). Earnings have declined by 6.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Revenue is less than US$5m (UK£1.4m revenue, or US$1.7m). Market cap is less than US$100m (UK£15.3m market cap, or US$19.2m). Announcement • Nov 11
Pds Biotech Announces Updated Survival Data from Nci-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients NetScientific Plc reported that its portfolio company, PDS Biotechnology Corporation has announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301 (IL-12 antibody-drug conjugate) and an investigational immune checkpoint inhibitor (ICI) in two groups of advanced cancer patients with various types of human papillomavirus (HPV) 16-positive cancers. The ICI naive group had not responded to standard-of-care treatments but had not yet been treated with an ICI. The ICI resistant group included patients who had not responded to multiple prior treatments, including ICI therapy. Investigators at the National Cancer Institute (NCI), part of the National Institutes of Health, have completed the primary endpoint analysis of the Phase 2 trial. In the ICI naive group, final survival data from the trial indicated that 75% (6/8) of these patients were still alive at 36 months, and the median overall survival (OS) has not yet been reached. Published data on standard-of-care ICIs report 30-50% of these patients typically remain alive at 12 months, and less than 30% of the patients remain alive at 24 months. In the ICI resistant group, the 12-month OS rate was 72% and the triple combination achieved a median OS of approximately 20 months. In addition: For PDS0101 plus high doses of ICI and PDS0301, the overall response rate (ORR) was 63% (5/8). The historical median survival for ICI therapy in HPV-positive cancer ICI resistant patients is reported to be 3.4 months. The ICI resistant data from the VERSATILE-002 trial evaluating PDS0101 in combination with KEYTRUDA®? (pembrolizumab) that were reported 3 October 2023, further clarify the path forward for a potential registrational clinical trial of PDS0101 and PDS0301 in combination with a commercial ICI. With this exciting information, the company will be finalising the regulatory and clinical pathway for the triple combination with OS as the primary endpoint. PDS0101, the company's lead candidate, is a Versamune®? based investigational immunotherapy designed to stimulate a potent targeted T cell attack against HPV16-positive cancers. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio. Reported Earnings • Oct 02
First half 2023 earnings released: UK£0.058 loss per share (vs UK£0.066 loss in 1H 2022) First half 2023 results: UK£0.058 loss per share (improved from UK£0.066 loss in 1H 2022). Net loss: UK£1.36m (loss narrowed 2.2% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Jun 06
NetScientific plc, Annual General Meeting, Jun 29, 2023 NetScientific plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Trowers & Hamlins LLP, 3 Bunhill Row London United Kingdom Reported Earnings • Jun 01
Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.13 loss in FY 2021) Full year 2022 results: UK£0.14 loss per share (further deteriorated from UK£0.13 loss in FY 2021). Net loss: UK£3.09m (loss widened 30% from FY 2021). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • May 31
NetScientific plc Announces Board Changes NetScientific plc announced that appointment of Charles Spicer as its new independent Non-Executive Chair. He will also chair the Nominations Committee and serve as a member of the Audit Committee and the Remuneration Committee. Charles will join the Company as a Non-Executive Director with immediate effect, and he will then assume the role of Non-Executive Chair following the closing of the Company's 2023 Annual General Meeting, which is anticipated to be on or around 29 June 2023. Interim Non-Executive Chair, Jonathan Robinson will continue in his role until the AGM, to facilitate an orderly handover. Following the AGM Jonathan will continue to serve on the Board as a Non-Executive Director, Senior Independent Director and Chair of both the Audit Committee and the Remuneration Committee. CharlesAlexander Evan Spicer (aged 58) is an experienced chair and director specialising in the medtech and life sciences industries. He advises both public and private companies. He currently chairs Creo Medical Group plc, IXICO plc, and Korn Wall Limited (KwickScreen). Furthermore, he serves as the Chair for the UK Department of Health's Product Development Awards Selection Panel B for Invention for Innovation (i4i). Charles previously held directorships at Aircraft Medical and Stanmore Implants. Charles was previously Chief Executive of MDY Healthcare plc and, prior to that, Head of Healthcare Corporate Finance at both Numis Securities and Nomura International. Charles has a PhD in History from London University and an MA in History from Cambridge University. Announcement • Feb 02
Netscientific plc Announces Board Changes NetScientific plc announces that, further to the Company's previous announcement on 9 November 2022, John Clarkson has stepped down as Chairman of the Company, and resigned from the Board with immediate effect. Jonathan Robinson, Non-Executive Director of the Company will now become Interim Non-Executive Chairman while the Company completes its recruitment process to appoint a new Chairman. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. General Counsel & Group Company Secretary Ed Hooper was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 30
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: UK£0.13 loss per share (further deteriorated from UK£0.11 loss in FY 2020). Net loss: UK£2.39m (loss widened 48% from FY 2020). Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Price Target Changed • Sep 30
Price target increased to UK£2.00 Up from UK£1.80, the current price target is an average from 2 analysts. New target price is 355% above last closing price of UK£0.44. Stock is down 65% over the past year. The company is forecast to post a net loss per share of UK£0.08 next year compared to a net loss per share of UK£0.13 last year. Reported Earnings • May 13
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: UK£0.13 loss per share (down from UK£0.11 loss in FY 2020). Net loss: UK£2.39m (loss widened 48% from FY 2020). Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 21%. Over the next year, revenue is forecast to grow 153%, compared to a 16% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Clive Sparrow was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 01
First half 2021 earnings released: UK£0.079 loss per share (vs UK£0.11 loss in 1H 2020) First half 2021 results: Net loss: UK£1.20m (loss widened 38% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Announcement • Jun 11
NetScientific plc has completed a Follow-on Equity Offering in the amount of £7.74556 million. NetScientific plc has completed a Follow-on Equity Offering in the amount of £7.74556 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,958,123
Price\Range: £1.3
Transaction Features: Subsequent Direct Listing Reported Earnings • Apr 20
Full year 2020 earnings released: UK£0.11 loss per share (vs UK£0.40 loss in FY 2019) Full year 2020 results: Net loss: UK£1.61m (loss narrowed 49% from FY 2019). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 02
Full year 2020 earnings released: UK£0.029 loss per share (vs UK£0.40 loss in FY 2019) Full year 2020 results: Net loss: UK£1.61m (loss narrowed 49% from FY 2019). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.